Research

LIke ThisLIke ThisLIke This

Cameron  Trenor, MD

Cameron Trenor
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Department:
Medicine Research
Division
Hematology/Oncology Research
Hospital Title:
Staff Physician; Co-Director, Cerebrovascular Disorders and Stroke Program; Director of Clinical Research - Vascular Anomalies Center
Academic Title:
Instructor in Pediatrics, Harvard Medical School
Research Focus Area:
Hematology/Oncology
Contact:
617-919-3242
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Trenor conducts basic science research on hemostasis and thrombosis in the laboratory of Drs. Bruce and Barbara Furie at Beth Israel Deaconess Medical Center. Currently funded by a K08 award from the NHLBI, this research currently focuses on platelet biology utilizing an in vivo model of laser-activated thrombosis.

Dr. Trenor also conducts clinical and translational research in vascular anomalies, stroke and thromboprophylaxis in pediatric patients. He is particularly interested in developing novel therapies for patients with vascular malformations and tumors. He currently is a co-PI for a phase 2 study of sirolimus in complex vascular anomalies and has additional trials in development for vascular anomalies. He is PI for a lymphatic anomalies registry and is developing a database of pediatric stroke patients.  He is a co-investigator in the International Paediatric Stroke Study and co-director of the Cerebrovascular Disorders and Stroke Program.

About Cameron Trenor

Dr. Trenor received his MD from the University of Tennessee Memphis. His general pediatric residency was in the Boston Combined Residency Program at Boston Children's Hospital and Boston Medical Center. His pediatric hematology-oncology fellowship training was at Boston Children's Hospital and Dana-Farber Cancer Institute.

Related Labs/Links

Vascular Anomalies Center

Cerebrovascular Disorders and Stroke Program


Publications

Publications powered by Harvard Catalyst Profiles
  1. Trenor CC. Medical management of vascular anomalies. Semin Cutan Med Surg. 2016 Sep; 35(3):177-81.
  2. Kelly DP, Bairdain S, Zurakowski D, Dodson B, Harney KM, Jennings RW, Trenor CC. Quality improvement program reduces venous thromboembolism in infants and children with long-gap esophageal atresia (LGEA). Pediatr Surg Int. 2016 Jul; 32(7):691-6.
  3. Goyal P, Alomari AI, Kozakewich HP, Trenor CC, Perez-Atayde AR, Fishman SJ, Greene AK, Shaikh R, Chaudry G. Imaging features of kaposiform lymphangiomatosis. Pediatr Radiol. 2016 Aug; 46(9):1282-90.
  4. Adams DM, Trenor CC, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016 Feb; 137(2):e20153257.
  5. Adams DM, Hammill AM, Mobberley-Schuman PS, Trenor CC. Comment on: Steroid-resistant kaposiform hemangioendothelioma: A retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer. 2015 Nov; 62(11):2056.
  6. Rankin H, Zwicker K, Trenor CC. Caution is recommended prior to sildenafil use in vascular anomalies. Pediatr Blood Cancer. 2015 Nov; 62(11):2015-7.
  7. Trenor CC, Fisher JG, Khan FA, Sparks EA, Duzan J, Harney K, Dillon B, Menard M, Modi BP. Paget-Schroetter syndrome in 21 children: outcomes after multidisciplinary care. J Pediatr. 2015 Jun; 166(6):1493-7.e1.
  8. Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr. 2015 Jan; 166(1):144-50.
  9. Uller W, Kozakewich HP, Trenor CC, O'Hare M, Alomari AI. Cutaneovisceral angiomatosis with thrombocytopenia without cutaneous involvement. J Pediatr. 2014 Oct; 165(4):876-876.e1.
  10. Trenor CC, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg. 2014 Aug; 23(4):186-90.
  11. Show all
  12. Orbach D, Storey A, Morash D, Estroff J, Smith E, Trenor C, Olson H. E-066 pathogenesis of dural sinus malformations as demonstrated by fetal imaging: a decision-making crucible for parents and clinicians. J Neurointerv Surg. 2014 Jul; 6 Suppl 1:A69-70.
  13. Zitomersky NL, Trenor CC. Authors' response. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6):e58.
  14. Bairdain S, Kelly DP, Tan C, Dodson B, Zurakowski D, Zurakowksi D, Jennings RW, Trenor CC. High incidence of catheter-associated venous thromboembolic events in patients with long gap esophageal atresia treated with the Foker process. J Pediatr Surg. 2014 Feb; 49(2):370-3.
  15. Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CC. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr. 2014 Feb; 164(2):383-8.
  16. Emani S, Zurakowski D, Baird CW, Pigula FA, Trenor C, Emani SM. Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery. Am J Hematol. 2014 Feb; 89(2):151-5.
  17. Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, Lightdale JR, Trenor CC. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):343-7.
  18. Drolet BA, Trenor CC, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul; 163(1):285-91.
  19. Emani S, Zurakowski D, Baird CW, Pigula FA, Trenor C, Emani SM. Hypercoagulability markers predict thrombosis in single ventricle neonates undergoing cardiac surgery. Ann Thorac Surg. 2013 Aug; 96(2):651-6.
  20. Emani S, Sista R, Loyola H, Trenor CC, Pamula VK, Emani SM. Novel microfluidic platform for automated lab-on-chip testing of hypercoagulability panel. Blood Coagul Fibrinolysis. 2012 Dec; 23(8):760-8.
  21. Barranco-Pons R, Burrows PE, Landrigan-Ossar M, Trenor CC, Alomari AI. Gross hemoglobinuria and oliguria are common transient complications of sclerotherapy for venous malformations: review of 475 procedures. AJR Am J Roentgenol. 2012 Sep; 199(3):691-4.
  22. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013 Jan; 162(1):142-7.
  23. Trenor CC. Sirolimus for refractory vascular anomalies. Pediatr Blood Cancer. 2011 Dec 1; 57(6):904-5.
  24. Zwicker JI, Trenor CC, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol. 2011 Apr; 31(4):728-33.
  25. Trenor CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011 Feb; 127(2):347-57.
  26. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011 Jan; 17(1):458-70.
  27. Trenor CC. Thrombosis and thrombophilia: principles for pediatric patients. Blood Coagul Fibrinolysis. 2010 Sep; 21 Suppl 1:S11-5.
  28. Trenor CC, Michelson AD. Thrombophilia and pediatric stroke. Circulation. 2010 Apr 27; 121(16):1795-7.
  29. Kentsis A, Bradwin G, Miller DT, Trenor CC. Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor. Am J Hematol. 2009 Nov; 84(11):775-6.
  30. Shin AY, Almond CS, Mannix RC, Duncan CN, Son MB, McLauchlan HM, Kanaan UB, Litzow JM, Riney PS, Trenor CC, Fortescue EB, Vinci RJ, Greenes DS. The Boston Marathon Study: a novel approach to research during residency. Pediatrics. 2006 May; 117(5):1818-22.
  31. Fleming MD, Campagna DR, Haslett JN, Trenor CC, Andrews NC. A mutation in a mitochondrial transmembrane protein is responsible for the pleiotropic hematological and skeletal phenotype of flexed-tail (f/f) mice. Genes Dev. 2001 Mar 15; 15(6):652-7.
  32. Trenor CC, Campagna DR, Sellers VM, Andrews NC, Fleming MD. The molecular defect in hypotransferrinemic mice. Blood. 2000 Aug 1; 96(3):1113-8.
  33. Su MA, Trenor CC, Fleming JC, Fleming MD, Andrews NC. The G185R mutation disrupts function of the iron transporter Nramp2. Blood. 1998 Sep 15; 92(6):2157-63.
  34. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997 Aug; 16(4):383-6.
  35. Trenor C, Lin W, Andrews NC. Novel bacterial P-type ATPases with histidine-rich heavy-metal-associated sequences. Biochem Biophys Res Commun. 1994 Dec 30; 205(3):1644-50.
  36. Lim JE, Jin O, Bennett C, Morgan K, Wang F, Trenor CC, Fleming MD, Andrews NC. A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet. 2005 Nov; 37(11):1270-3.
  37. Romero FJ, Martínez-Blasco A, Bosch-Morell F, Marín N, Trenor C, Romá J. Glycemic control and not protein kinase C inhibition prevents the early decrease of glutathione peroxidase activity in peripheral nerve of diabetic mice. J Peripher Nerv Syst. 1999; 4(3-4):265-9.
  38. Martínez-Blasco A, Bosch-Morell F, Trenor C, Romero FJ. Experimental diabetic neuropathy: role of oxidative stress and mechanisms involved. Biofactors. 1998; 8(1-2):41-3.
  39. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001 Aug; 108(4):619-23.
  40. Kurek KC, Howard E, Tennant LB, Upton J, Alomari AI, Burrows PE, Chalache K, Harris DJ, Trenor CC, Eng C, Fishman SJ, Mulliken JB, Perez-Atayde AR, Kozakewich HP. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol. 2012 May; 36(5):671-87.
  41. Alomari AI, Spencer SA, Arnold RW, Chaudry G, Kasser JR, Burrows PE, Govender P, Padua HM, Dillon B, Upton J, Taghinia AH, Fishman SJ, Mulliken JB, Fevurly RD, Greene AK, Landrigan-Ossar M, Paltiel HJ, Trenor CC, Kozakewich HP. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity. J Pediatr Orthop. 2014 Jan; 34(1):109-17.
  42. Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovée JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015 Apr; 166(4):1048-54.e1-5.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more
Close